No press releases found.
Neuphoria Launches Strategic Review After Unsolicited Buyout Proposal and Director Nominations
Market Chameleon (Tue, 11-Nov 4:17 AM ET)
Market Chameleon (Tue, 21-Oct 3:05 AM ET)
Market Chameleon (Wed, 12-Feb 3:37 AM ET)
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
Neuphoria Therapeutics trades on the NASDAQ stock market under the symbol NEUP.
As of March 13, 2026, NEUP stock price declined to $4.54 with 116,774 million shares trading.
NEUP has a beta of -0.25, meaning it tends to be less sensitive to market movements. NEUP has a correlation of 0.00 to the broad based SPY ETF.
NEUP has a market cap of $24.47 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that NEUP belongs to (by Net Assets): PSIL, VTI, VXF.
NEUP has underperformed the market in the last year with a return of -6.2%, while SPY returned +21.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in NEUP shares. However, NEUP has outperformed the market in the last 3 month and 2 week periods, returning +11.3% and +9.4%, while SPY returned -2.6% and -3.5%, respectively. This indicates NEUP has been having a stronger performance recently.
NEUP support price is $4.52 and resistance is $4.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NEUP shares will trade within this expected range on the day.